Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
Papatheodoridis GV, Manesis EK, Manolakopoulos S, Elefsiniotis IS, Goulis J, Giannousis J, Bilalis A, Kafiri G, Tzourmakliotis D, Archimandritis AJ. Papatheodoridis GV, et al. Among authors: elefsiniotis is. Hepatology. 2008 Nov;48(5):1451-9. doi: 10.1002/hep.22518. Hepatology. 2008. PMID: 18924246
Ultrasensitive amplification refractory mutation system real-time PCR (ARMS RT-PCR) assay for detection of minority hepatitis B virus-resistant strains in the era of personalized medicine.
Ntziora F, Paraskevis D, Haida C, Manesis E, Papatheodoridis G, Manolakopoulos S, Elefsiniotis I, Karamitros T, Vassilakis A, Hatzakis A. Ntziora F, et al. J Clin Microbiol. 2013 Sep;51(9):2893-900. doi: 10.1128/JCM.00936-13. Epub 2013 Jun 26. J Clin Microbiol. 2013. PMID: 23804383 Free PMC article.
HERACLIS-TAF: a multi-centre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks.
Papatheodoridis GV, Mimidis K, Manolakopoulos S, Gatselis N, Goulis J, Kapatais A, Manesis E, Vasiliadis T, Triantos C, Samonakis D, Sevastianos V, Karatapanis S, Elefsiniotis I, Deutsch M, Mylopoulou T, Papatheodoridi M, Kranidioti H, Agorastou P, Karaoulani T, Kyriazidou A, Zisimopoulos K, Dalekos GN. Papatheodoridis GV, et al. Aliment Pharmacol Ther. 2022 Aug;56(4):702-712. doi: 10.1111/apt.17093. Epub 2022 Jun 23. Aliment Pharmacol Ther. 2022. PMID: 35736010
Aiming towards hepatitis C virus elimination in Greece.
Papatheodoridis GV, Goulis J, Sypsa V, Lionis C, Manolakopoulos S, Elefsiniotis I, Anagnostou O, Tsoulas C, Hatzakis A, Dalekos GN. Papatheodoridis GV, et al. Ann Gastroenterol. 2019 Jul-Aug;32(4):321-329. doi: 10.20524/aog.2019.0375. Epub 2019 Apr 5. Ann Gastroenterol. 2019. PMID: 31263353 Free PMC article.
Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis.
Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, Antonakaki P, Vlachogiannakos J, Triantos C, Elefsiniotis I, Goulis J, Mela M, Anagnostou O, Tsoulas C, Deutsch M, Papatheodoridis G, Manolakopoulos S. Kranidioti H, et al. Ann Gastroenterol. 2018 Sep-Oct;31(5):598-603. doi: 10.20524/aog.2018.0293. Epub 2018 Jul 19. Ann Gastroenterol. 2018. PMID: 30174397 Free PMC article.
84 results